Study Details
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria
Clinicaltrials.gov ID
Astellas Study ID
1941-MA-3122-KR
EudraCT ID
N/A
Condition
Adult Onset Diabetes
Phase
Phase 4
Age
19 years - 74 years
Sex
Female & Male
Product
N/A
Type
Interventional
Trial Dates
Apr 2017 - Dec 2018
Masking
None (Open Label)
Enrollment number
33
A Phase 4, Randomized, Open-label, Active-controlled, Multicenter Study to Evaluate the Renal Protective Effect (UACR), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria
Study summary
Study documents
Get More Information
Would you like more information about clinical trial sites that are recruiting participants for A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus patients with Albuminuria? Contact us by filling our your information to the right and we’ll respond to you.
Locations
Site 02
Deagu, Republic of Korea
Site 07
Seoul, Republic of Korea
Site 10
Seoul, Republic of Korea
Site 06
Daejeon, Republic of Korea
Site 15
Bucheon-si, Republic of Korea
Site 12
Suwon-si, Republic of Korea
Site 17
Seoul, Republic of Korea
Site 04
Bucheon-si, Gyueonggi-do, Republic of Korea
Site 11
Guri-si, Republic of Korea
Site 05
Seoul, Republic of Korea
Site 03
Goyang-si, Gyueonggi-do, Republic of Korea
Site 09
Seoul, Republic of Korea
Site 18
Seoul, Republic of Korea
Site 13
Busan, Republic of Korea
Site 08
Gwangju, Republic of Korea
Site 14
Seoul, Republic of Korea
Site 01
Seoul, Republic of Korea